VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development ...

Another wave of layoffs has hit one of the Bay Area's biggest biotech companies—and the latest cuts push a troubling trend ...

New York invests $65M in biotech with new clinical trial consortium and Biogenesis Park to compete with Boston, San Francisco ...

Discover Prague's biotech hub, now viewed as the primary ‘entry gateway’ into the wider Central and Eastern European ...

On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing ...

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for ...

BioProcess International reviews key biotech trends from the first half of 2026, including US onshoring, China's biologics ...

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping the future of aging research.

In South San Francisco, Genentech showed that recombinant DNA technology could transform medicine and create therapies once ...

Based on its sound industrial ecosystem and strong policy support, Zhangjiang Pharma Valley in Shanghai is witnessing ...

Seeking biotech investment, breakthrough innovations, or a strategic gateway to the Asia-Pacific? The answers await in Hong Kong this September.HONG KONG, July 7, 2026 /PRNewswire/ -- The 5th Hong ...

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...